This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Ascendis Pharma Management
Management criteria checks 2/4
Ascendis Pharma's CEO is Jan Mikkelsen, appointed in Dec 2007, has a tenure of 18.33 years. directly owns 0.62% of the company’s shares, worth €76.13M. The average tenure of the management team and the board of directors is 9.7 years and 7.4 years respectively.
Key information
Jan Mikkelsen
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
18.3yrs
CEO ownership
0.6%
Management average tenure
9.7yrs
Board average tenure
7.4yrs
Recent management updates
Recent updates
CEO
Jan Mikkelsen (65 yo)
18.3yrs
Tenure
Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Jan Mikkelsen
President
18.3yrs
no data
0.62% € 76.1m
Scott Smith
CFO, Executive VP & Member of Executive Board
9.7yrs
no data
0.0041% € 497.3k
Pedersen Anni Lotte Sonderbjerg
Executive VP
18.3yrs
no data
0.032% € 3.8m
Michael Jensen
Executive VP
12.8yrs
no data
0% € 0
Mads Bodenhoff
Senior VP
2.2yrs
no data
0.00031% € 37.9k
Chad Fugure
Vice President of Investor Relations
no data
no data
no data
Flemming Jensen
Executive Vice President of Product Supply & Quality
10.7yrs
no data
0.032% € 3.8m
Kennett Sprogoe
Executive VP and Head of Research & Product Development
10.3yrs
no data
0.032% € 3.9m
Stina Singel
Executive VP & Head of Clinical Development for Oncology
4.3yrs
no data
no data
Joseph Kelly
Head of U.S. Commercial of Endocrinology
3.9yrs
no data
no data
Sherrie Glass
Chief Business Officer
1.6yrs
no data
0% € 0
Jay Wu
Executive VP & President of Ascendis US
1.3yrs
no data
0.0017% € 211.4k
9.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: A71's management team is seasoned and experienced (9.7 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Jan Mikkelsen
President
18.3yrs
no data
0.62% € 76.1m
Albert Cha
Independent Chairman
11.4yrs
€139.72k
0.0060% € 738.0k
William Fairey
Independent Director
3.6yrs
€73.01k
0.0034% € 419.1k
Lisa Morrison
Independent Director
9yrs
€92.64k
0.0025% € 310.4k
Lars Holtug
Independent Director
7.4yrs
€96.17k
0.0069% € 838.2k
Siham Imani
Independent Director
3.6yrs
€69.48k
0.0037% € 458.2k
Jean-Jacques Bienaime
Non-Executive Director
less than a year
no data
no data
7.4yrs
Average Tenure
58.5yo
Average Age
Experienced Board: A71's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/04/23 10:01
End of Day Share Price
2026/04/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascendis Pharma A/S is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.